That may be true, but I also recall the safety data came back more mixed because of how PYMX interpreted/classified those patients ( many in the Ukraine ) who were treated but then dropped out of sight ( ie no followup ) -- many on this board saw this as a possible measure of efficacy a la "one dose that's all" instead of as an adverse outcome. I wasn't following CTIX as closely then as I am now but if memory serves me correct this was a factor beyond the dosing amts and frequency issue you cite. Either way, the ph 2b was safer due to better trial design it seems compliments of Menon's expertise. Thx for the comment. New eyes to the board might appreciate the exchange.
Market Data 
Markets 
AI
